Drugs / Propagermanium
Propagermanium
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05122182 | Jan → Aug 2022 | COVID-19 | University of Sydney | Terminated | No outcome recorded |
| Phase 2 | NCT03649152 | Nov 2018 → Jun 2020 | primary focal segmental glomerulosclerosis | Dimerix Bioscience Pty Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03627715 | Nov 2018 → Jul 2020 | diabetic kidney disease | Dimerix Bioscience Pty Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05183646 | May 2022 → Dec 2029 expected | focal segmental glomerulosclerosis | Dimerix Bioscience Pty Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Propagermanium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03627715 ↗ |
| Known as | DMX-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02735707 ↗ |
| Known as | Repagermanium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05122182 ↗ |
| Action | Inhibit | “CCR2 antagonist” NCT05122182 ↗ |
| Route | Oral | “Propagermanium one capsule orally twice daily for 12 weeks.” NCT03627715 ↗ |